AA
RNAM

AlphaCentric Advisors’s Avidity Biosciences RNAM Stock Holding History

AlphaCentric Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,995
Closed -$505K – 295
2025
Q4 		$505K Buy
+6,995
New +$452K 0.5% 63

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

AlphaCentric Advisors's RNAM Position: Q1 2026 in Review

AlphaCentric Advisors sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 6,995 shares — an estimated $505K sold.

AlphaCentric Advisors first reported a position in RNAM in Q4 2025 and held it in 1 quarter. The position peaked at $505K in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • AlphaCentric Advisors reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • AlphaCentric Advisors sold 6,995 Avidity Biosciences shares in Q1 2026, an estimated $505K.
  • AlphaCentric Advisors first reported a position in Avidity Biosciences in Q4 2025 and held it in 1 quarter.
  • AlphaCentric Advisors's Avidity Biosciences position peaked at $505K in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.